Hemolytic-uremic syndrome secondary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(3 intermediate revisions by one other user not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{HUS}}
{{HUS}}
{{CMG}}; {{AE}}  
{{CMG}} {{shyam}}; {{AE}} {{S.G.}}


==Overview==
==Overview==
There are no established measures for the secondary prevention of [disease name].
[[Hydration]] and supportive [[therapy]] can restrict [[complications]].
 
OR
 
Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].


==Secondary Prevention==
==Secondary Prevention==
Effective measures for the secondary prevention of HUS include:<ref name="Grisaru2014">{{cite journal|last1=Grisaru|first1=Silviu|title=Management of hemolytic-uremic syndrome in children|journal=International Journal of Nephrology and Renovascular Disease|year=2014|pages=231|issn=1178-7058|doi=10.2147/IJNRD.S41837}}</ref><ref>{{Cite journal
Effective measures for the [[Secondary Prevention'''|secondary prevention]] of HUS include:<ref name="Grisaru2014">{{cite journal|last1=Grisaru|first1=Silviu|title=Management of hemolytic-uremic syndrome in children|journal=International Journal of Nephrology and Renovascular Disease|year=2014|pages=231|issn=1178-7058|doi=10.2147/IJNRD.S41837}}</ref><ref>{{Cite journal
  | author = [[Hoon Young Choi]] & [[Sung Kyu Ha]]
  | author = [[Hoon Young Choi]] & [[Sung Kyu Ha]]
  | title = Potassium balances in maintenance hemodialysis
  | title = Potassium balances in maintenance hemodialysis
Line 24: Line 20:
}}</ref><ref>{{cite journal|doi=10.1007/s00467-018-4025-0 Share on FacebookShare on TwitterShare on Google+}}</ref>
}}</ref><ref>{{cite journal|doi=10.1007/s00467-018-4025-0 Share on FacebookShare on TwitterShare on Google+}}</ref>


*Supportive therapy and hydration
*Supportive [[therapy]] and [[hydration]]
*Obsereved closely
*Close observation for worsening clinical status
*Use eculizumab in aHUS
*Use of [[eculizumab]] in atypical HUS
*Avoidance of nephrotoxic medications


==References==
==References==

Latest revision as of 02:40, 21 December 2018

Hemolytic-uremic syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hemolytic-uremic syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hemolytic-uremic syndrome secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hemolytic-uremic syndrome secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hemolytic-uremic syndrome secondary prevention

CDC on Hemolytic-uremic syndrome secondary prevention

Hemolytic-uremic syndrome secondary prevention in the news

Blogs on Hemolytic-uremic syndrome secondary prevention

Directions to Hospitals Treating Hemolytic-uremic syndrome

Risk calculators and risk factors for Hemolytic-uremic syndrome secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [3]

Overview

Hydration and supportive therapy can restrict complications.

Secondary Prevention

Effective measures for the secondary prevention of HUS include:[1][2][3]

  • Supportive therapy and hydration
  • Close observation for worsening clinical status
  • Use of eculizumab in atypical HUS
  • Avoidance of nephrotoxic medications

References

  1. Grisaru, Silviu (2014). "Management of hemolytic-uremic syndrome in children". International Journal of Nephrology and Renovascular Disease: 231. doi:10.2147/IJNRD.S41837. ISSN 1178-7058.
  2. Hoon Young Choi & Sung Kyu Ha (2013). "Potassium balances in maintenance hemodialysis". Electrolyte & blood pressure : E & BP. 11 (1): 9–16. doi:10.5049/EBP.2013.11.1.9. PMID 23946760. Unknown parameter |month= ignored (help)
  3. . doi:10.1007/s00467-018-4025-0 Share on FacebookShare on TwitterShare on Google+ Check |doi= value (help). Missing or empty |title= (help)

Template:WH Template:WS